FOXO Technologies Inc. Regains Compliance with NYSE American Listing Standards

FOXO Technologies Inc. (NYSEAMERICAN: FOXO) has officially announced that it has addressed its previous listing deficiencies with NYSE American LLC. The company received a notification on December 16, 2024, indicating that it is now in compliance with all continued listing standards specified in Part 10 of the NYSE American Company Guide.

The notification specifically confirmed that FOXO Technologies is compliant with Sections 1003(a)(i) and (ii) of the Company Guide. These compliance issues were previously raised in correspondence from the Exchange dated June 12, 2023, and July 10, 2024.

Despite regaining compliance, FOXO Technologies Inc. will continue to be monitored under the standard protocols of NYSE Regulation. As per Section 1009(h) of the Company Guide, if the company fails to maintain these standards within 12 months, it may face reassessment regarding its recovery efforts. Such reassessment could lead to either expedited compliance measures or, in severe cases, immediate delisting considerations.

With the reinstatement of compliance effective December 17, 2024, the “.BC” indicator will no longer be shown, removing FOXO from the roster of noncompliant issuers on the NYSE American exchange.

FOXO Technologies Inc. has reassured its investors and stakeholders of its commitment to adhere to all relevant regulations and maintain compliance. CEO Seamus Lagan endorsed this report, emphasizing FOXO's commitment to not only meeting but exceeding the listing standards.

This positive outcome is a significant milestone for FOXO Technologies Inc., reflecting its dedication to uphold high standards of governance and compliance within the NYSE American framework.

About FOXO Technologies

FOXO Technologies Inc. operates in the realm of epigenetic biomarker underwriting technology and provides consumer engagement platform services in the United States. The company runs two segments: FOXO Labs and FOXO Life. Utilizing automated machine learning and artificial intelligence, FOXO discovers epigenetic biomarkers that pertain to human health, wellness, and aging.

FOXO, Compliance, NYSE